AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35138325 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP
Number of subjects: 136
Study 35138325 — intervention group
Group type: EXPERIMENTAL
Intervention: hsTnI
Number of subjects: 136
Study 35138325 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential algorithm using 3-D LVEF, GLS, and GCS
Number of subjects: 136
Study 35138325 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-D LVEF
Number of subjects: 136
Study 35138442 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate DOAC dosage
Number of subjects: 253
Study 35138442 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate DOAC dosage
Number of subjects: 253
Study 35138442 — intervention group
Group type: EXPERIMENTAL
Intervention: Underdosage
Number of subjects: 253
Study 35138442 — intervention group
Group type: EXPERIMENTAL
Intervention: Overdosage
Number of subjects: 253
Study 35138442 — intervention group
Group type: COMPARATOR
Intervention: Survival comparison between underdosage and appropriate dosage
Number of subjects: 253
Study 35138444 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative classification and radiomics
Number of subjects: 123
Study 35138474 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 107
Study 35138529 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg/day
Number of subjects: 87
Study 35138529 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib plus vinorelbine 25 mg/m
Number of subjects: 87
Study 35138529 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib plus paclitaxel
Number of subjects: 87
Study 35138529 — intervention group
Group type: COMPARATOR
Intervention: Afatinib monotherapy
Number of subjects: 87
Study 35138529 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (afatinib plus vinorelbine or paclitaxel)
Number of subjects: 87
Study 35138562 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (150,000 IU)
Number of subjects: 34
Study 35138670 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Frailty Scale (CFS)
Number of subjects: 2191
Study 35138670 — intervention group
Group type: COMPARATOR
Intervention: Emergency Severity Index (ESI)
Number of subjects: 2191
Study 35138678 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP initiation at first ANC visit
Number of subjects: 1201
Study 35138678 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP continuation after 1 month
Number of subjects: 1201
Study 35138678 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP continuation after 3 months
Number of subjects: 1201
Study 35138678 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects reported at 1 month
Number of subjects: 1201
Study 35138678 — intervention group
Group type: EXPERIMENTAL
Intervention: Odds of reporting side effects for women in first and second trimesters
Number of subjects: 1201
Study 35138678 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of PrEP for women reporting side effects
Number of subjects: 1201
Study 35138678 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of PrEP for women with ≥1 previous pregnancy
Number of subjects: 1201
Study 35138678 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of PrEP for postpartum women
Number of subjects: 1201
Study 35138678 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of PrEP for women with HIV+ partners
Number of subjects: 1201
Study 35138678 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of PrEP for women with high HIV risk perception
Number of subjects: 1201
Study 35138919 — intervention group
Group type: EXPERIMENTAL
Intervention: Taselisib monotherapy
Number of subjects: 70
Study 35139037 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal colonization
Number of subjects: 0
Study 35139119 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive and dignified maternity care (SDMC) intervention package including capacity-building of maternity teams and improvement of governance and accountability mechanisms.
Number of subjects: 0
Study 35139119 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive and dignified maternity care (SDMC) intervention package.
Number of subjects: 0
Study 35139264 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic post-surgical neuropathic pain (CPSNP) patients
Number of subjects: 241
Study 35139264 — intervention group
Group type: COMPARATOR
Intervention: Non-CPSNP patients
Number of subjects: 241
Study 35139264 — intervention group
Group type: EXPERIMENTAL
Intervention: CPSNP patients
Number of subjects: 241
Study 35139264 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test (CPT)
Number of subjects: 241
Study 35139856 — intervention group
Group type: EXPERIMENTAL
Intervention: PET/CT-based adaptive radiotherapy planning
Number of subjects: 347
Study 35139856 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent planning strategy
Number of subjects: 347
Study 35139856 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor volume change during chemoradiotherapy
Number of subjects: 347
Study 35139860 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acids (omega-3 PUFA)
Number of subjects: 0
Study 35139860 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35139888 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous adipose-derived stromal vascular fraction (ADSVF) combined with microfat
Number of subjects: 10
Study 35139888 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 10
Study 35139911 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic electronic screening for substance use and mental health symptoms via secure messaging and clinic-based tablets, integrated into the electronic health record (EHR).
Number of subjects: 21
Study 35139911 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple methods of questionnaire completion (secure messaging and clinic-based tablets).
Number of subjects: 21
Study 35139911 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-provider relationship.
Number of subjects: 21
Study 35139911 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to screening (privacy and confidentiality concerns, potential burden from repeated screenings).
Number of subjects: 21
Study 35140147 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided diagnosis system (CAD)
Number of subjects: 420
Study 35140147 — intervention group
Group type: COMPARATOR
Intervention: Prostate Imaging-Reporting and Data System V.2.1 (PI-RADS V.2.1)
Number of subjects: 420
Study 35140147 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PHI and MRI findings
Number of subjects: 420
Study 35140164 — intervention group
Group type: EXPERIMENTAL
Intervention: Feelix Smart Stethoscope
Number of subjects: 1000
Study 35140164 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated algorithm for lung sound interpretation
Number of subjects: 1000
Study 35140164 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated algorithm
Number of subjects: 1000
Study 35140619 — intervention group
Group type: EXPERIMENTAL
Intervention: CMAB807, a new Denosumab biosimilar
Number of subjects: 0
Study 35141162 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD-M regimen (Gemcitabine, Peg-Asparaginase, Dexamethasone, Methotrexate) administered for 6 cycles
Number of subjects: 36
Study 35141162 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD-M regimen with radiotherapy for stage I/II patients
Number of subjects: 36
Study 35141162 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD-M regimen for stage III/IV patients
Number of subjects: 36
Study 35141162 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD-M regimen
Number of subjects: 36
Study 35141162 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma MTX concentration ratio at 12 to 24 hr during the first cycle
Number of subjects: 36
Study 35141170 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic model based on age, fever at admission, and haematological parameters
Number of subjects: 577
Study 35141170 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic model applied during temporal-external validation
Number of subjects: 577
Study 35141170 — intervention group
Group type: EXPERIMENTAL
Intervention: Haematological parameters (lactate dehydrogenase, platelet count, C-reactive protein, creatinine)
Number of subjects: 577
Study 35141572 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese group (BMI ≥30)
Number of subjects: 61
Study 35141572 — intervention group
Group type: COMPARATOR
Intervention: Normal weight group (BMI 18.5-24.9)
Number of subjects: 61
Study 35141873 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone
Number of subjects: 2023
Study 35141873 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 2023
Study 35141873 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 2023
Study 35141873 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 2023
Study 35141873 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 2023
Study 35141873 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 2023
Study 35141873 — intervention group
Group type: EXPERIMENTAL
Intervention: PulmoCare enteral formula
Number of subjects: 2023
Study 35141873 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxepa enteral formula
Number of subjects: 2023
Study 35141873 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan
Number of subjects: 2023
Study 35142618 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient portal research recruitment invitation
Number of subjects: 4510
Study 35142618 — intervention group
Group type: EXPERIMENTAL
Intervention: Opened patient portal invitation
Number of subjects: 4510
Study 35142618 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient portal invitation
Number of subjects: 4510
Study 35142618 — intervention group
Group type: EXPERIMENTAL
Intervention: Opened research invitation
Number of subjects: 4510
Study 35142658 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbasvir/Grazoprevir (ELB/GZR) for 8 weeks
Number of subjects: 30
Study 35143011 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS adherence (highest adherence quartile, Q1)
Number of subjects: 1419
Study 35143011 — intervention group
Group type: COMPARATOR
Intervention: Self-designated ERAS group
Number of subjects: 1419
Study 35143750 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective contraceptive method
Number of subjects: 122
Study 35143750 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about pregnancy-related risks
Number of subjects: 122
Study 35143750 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about planning pregnancy
Number of subjects: 122
Study 35143750 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of preconception HbA1c target
Number of subjects: 122
Study 35143750 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate knowledge about pregnancy
Number of subjects: 122
Study 35143750 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of contraindicated contraceptive method
Number of subjects: 122
Study 35143750 — intervention group
Group type: EXPERIMENTAL
Intervention: No contraceptive method despite recommendation
Number of subjects: 122
Study 35143771 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2-positive adolescents
Number of subjects: 24315
Study 35144270 — intervention group
Group type: EXPERIMENTAL
Intervention: Normocephalic infants
Number of subjects: 219
Study 35144270 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmentally delayed group
Number of subjects: 219
Study 35144270 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory abnormalities
Number of subjects: 219
Study 35144482 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab
Number of subjects: 0
Study 35144482 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35144487 — intervention group
Group type: EXPERIMENTAL
Intervention: NASH score (predictive model)
Number of subjects: 918
Study 35144521 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep-disordered breathing intervention
Number of subjects: 0
Study 35144521 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35144742 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprocedural MI defined by the third UDMI
Number of subjects: 4404
Study 35144742 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprocedural MI defined by the fourth UDMI
Number of subjects: 4404
Study 35144742 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprocedural MI defined by ARC-2
Number of subjects: 4404
Study 35144742 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprocedural MI defined by SCAI
Number of subjects: 4404
Study 35144789 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular baroreflex amplification (EVBA) with the Mobius device
Number of subjects: 47
Study 35144802 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in cerebrospinal fluid/plasma albumin ratio (CPAR)
Number of subjects: 103
Study 35144802 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma S100B
Number of subjects: 103
Study 35144802 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood loss
Number of subjects: 103
Study 35144847 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACYW-TT conjugate vaccine co-administered with routine pediatric vaccines (DTaP-IPV/Hib, PCV7/PCV13, MMR, and varicella)
Number of subjects: 0
Study 35144847 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACYW-TT conjugate vaccine
Number of subjects: 0
Study 35144847 — intervention group
Group type: COMPARATOR
Intervention: Routine pediatric vaccines
Number of subjects: 0
Study 35144953 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent TBS (iTBS) on left DLPFC
Number of subjects: 70
Study 35144953 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous TBS (cTBS) on right DLPFC
Number of subjects: 70
Study 35144953 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks of daily iTBS treatment of left DLPFC
Number of subjects: 70
Study 35144989 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on inhaled budesonide
Number of subjects: 0
Study 35145218 — intervention group
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T (3 infusions)
Number of subjects: 199
Study 35145465 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic cognitive training combined with physical exercise for 12 weeks
Number of subjects: 0
Study 35145465 — intervention group
Group type: COMPARATOR
Intervention: Standard HD care
Number of subjects: 0
Study 35145478 — intervention group
Group type: EXPERIMENTAL
Intervention: ANGPTL8
Number of subjects: 551
Study 35145478 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin
Number of subjects: 551
Study 35145638 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline pNGAL measurement
Number of subjects: 698
Study 35145638 — intervention group
Group type: EXPERIMENTAL
Intervention: pNGAL
Number of subjects: 698
Study 35146146 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal RDN
Number of subjects: 55
Study 35146146 — intervention group
Group type: COMPARATOR
Intervention: Main trunk RDN
Number of subjects: 55
Study 35146939 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusional gemcitabine (100 mg/m) with concurrent radiotherapy (50.4-54 Gy over 28 days)
Number of subjects: 40
Study 35147501 — intervention group
Group type: EXPERIMENTAL
Intervention: Onduo virtual care program with telemedicine consultations and RT-CGM
Number of subjects: 55
Study 35147501 — intervention group
Group type: EXPERIMENTAL
Intervention: Onduo virtual care program
Number of subjects: 55
Study 35147580 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP (Pre-Exposure Prophylaxis)
Number of subjects: 348
Study 35147794 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendees of the FICS annual meeting
Number of subjects: 520
Study 35147794 — intervention group
Group type: COMPARATOR
Intervention: Matched controls (healthcare professionals who stayed in the ICU)
Number of subjects: 520
Study 35148417 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19/CD28ζ CAR T-cells
Number of subjects: 52
Study 35148720 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted HIV-1 nucleic acid (NA) testing intervention
Number of subjects: 1500
Study 35148720 — intervention group
Group type: COMPARATOR
Intervention: Standard provider-initiated testing using rapid antibody tests
Number of subjects: 1500
Study 35148734 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted minimally invasive surgery (RA-MIS)
Number of subjects: 208
Study 35148734 — intervention group
Group type: COMPARATOR
Intervention: Robot-assisted open surgery (RA-OS)
Number of subjects: 208
Study 35148798 — intervention group
Group type: COMPARATOR
Intervention: Otago alone (Arm 1)
Number of subjects: 30
Study 35148798 — intervention group
Group type: EXPERIMENTAL
Intervention: Otago + Gentle Yoga and Yogic Breathing (Arm 2)
Number of subjects: 30
Study 35148798 — intervention group
Group type: EXPERIMENTAL
Intervention: Otago + Gentle Yoga and Yogic Breathing + Behavioral Activation (Arm 3)
Number of subjects: 30
Study 35148892 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 0
Study 35148892 — intervention group
Group type: COMPARATOR
Intervention: Sleep/Propofol
Number of subjects: 0
Study 35149207 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial stiffness (pulse wave velocity measures: carotid-femoral, femoral-foot, carotid-radial, augmentation index, brachial distensibility)
Number of subjects: 388
Study 35149207 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial stiffness
Number of subjects: 388
Study 35149587 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of G9a and EZH2
Number of subjects: 0
Study 35149587 — intervention group
Group type: COMPARATOR
Intervention: Control (normal cells)
Number of subjects: 0
Study 35149591 — intervention group
Group type: EXPERIMENTAL
Intervention: VCN-01 administered intratumorally at doses up to 1×10,
Number of subjects: 0
Study 35149591 — intervention group
Group type: EXPERIMENTAL
Intervention: VCN-01 combined with standard chemotherapy,
Number of subjects: 0
Study 35149591 — intervention group
Group type: EXPERIMENTAL
Intervention: VCN-01,
Number of subjects: 0
Study 35149627 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Care for Heart Failure Index v6.2
Number of subjects: 195
Study 35149627 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep characteristics
Number of subjects: 195
Study 35149627 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 195
Study 35149627 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction of <45
Number of subjects: 195
Study 35149627 — intervention group
Group type: EXPERIMENTAL
Intervention: White race
Number of subjects: 195
Study 35149641 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir (90 mg/400 mg) once daily for 12 weeks
Number of subjects: 19
Study 35149851 — intervention group
Group type: EXPERIMENTAL
Intervention: BeEAM (Bendamustine-EAM)
Number of subjects: 280
Study 35149851 — intervention group
Group type: COMPARATOR
Intervention: R-BEAM
Number of subjects: 280
Study 35149868 — intervention group
Group type: EXPERIMENTAL
Intervention: cMyC 0/1h-algorithm
Number of subjects: 1495
Study 35149871 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiota maturity and diversity
Number of subjects: 611
Study 35149871 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual taxa (Bifidobacterium and Enterobacteriaceae)
Number of subjects: 611
Study 35150024 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-loving attitudes
Number of subjects: 675
Study 35150024 — intervention group
Group type: COMPARATOR
Intervention: Risky behaviors and time preferences
Number of subjects: 675
Study 35150293 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dobutamine (LDD) stress test at 10 µg/kg/min
Number of subjects: 52
Study 35150293 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dobutamine (LDD) stress test at 5, 10, 15 µg/kg/min
Number of subjects: 52
Study 35150293 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dobutamine (LDD) stress test
Number of subjects: 52
Study 35150296 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-yttrium-ibritumomab tiuxetan (90Y-IT) as first-line treatment
Number of subjects: 59
Study 35150356 — intervention group
Group type: EXPERIMENTAL
Intervention: M3541 (50-300 mg administered on RT fraction days)
Number of subjects: 15
Study 35150355 — intervention group
Group type: COMPARATOR
Intervention: Supine-baseline
Number of subjects: 15
Study 35150355 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine-final
Number of subjects: 15
Study 35150355 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential postural recruitment maneuver
Number of subjects: 15
Study 35150403 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital lifestyle management tool
Number of subjects: 297
Study 35151024 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-led responses to opioid prescribing practices
Number of subjects: 388
Study 35151024 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare provider education and prescription drug monitoring programs
Number of subjects: 388
Study 35151024 — intervention group
Group type: EXPERIMENTAL
Intervention: Safer opioid prescribing guidelines
Number of subjects: 388
Study 35151176 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-item odorant test (U-Smell-It™)
Number of subjects: 1320
Study 35151262 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-axis turntable based BPPV treatment
Number of subjects: 75
Study 35151262 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular testing for BPPV and treatment with appropriate liberation maneuvers
Number of subjects: 75
Study 35151268 — intervention group
Group type: EXPERIMENTAL
Intervention: Diosmectite (3 g/sachet, 3 sachets/day)
Number of subjects: 35
Study 35151310 — intervention group
Group type: EXPERIMENTAL
Intervention: PHARM-DC intervention
Number of subjects: 10
Study 35151584 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg IV infusion every 3 weeks) plus Tazemetostat (800 mg orally BID on days 1 to 21)
Number of subjects: 43
Study 35152218 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous history of falls
Number of subjects: 66
Study 35152218 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal posture
Number of subjects: 66